CHCWM – Cancer & Hematology Centers of West Michigan

C4391002  (Pfizer)

Description:  Phase 1B/2, Open Label, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PF-07220060 in Combination with PF-07104091 Plus Endocrine Therapy in participants with Advanced Solid Tumor

Mechanism of Action:  CDK2 inhibitor + CDK4 inhibitor

Target Patient Population:   All solid tumors, but is especially attractive for HR+, HER2- breast cancer

Study Design:  Drug is given orally twice daily.